Plain-English translation of NCT05023018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing whether , a new experimental medication, can help treat high-grade meningiomas—aggressive brain tumors that either come back after treatment, continue to grow, or weren't completely removed by surgery. The trial will enroll 30 patients with this type of tumor to see if the medication is safe and effective. This research is important because current treatments (surgery and radiation) don't always work for everyone, and doctors need better options.
Most people with high-grade meningiomas face a difficult problem: surgery alone may not remove all the tumor, especially if it's located near sensitive parts of the brain, and tumors often come back. There are very few proven medications available for these aggressive brain tumors, so researchers are testing this treatment to see if it can help patients who have already tried surgery and radiation without complete success.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive as your study treatment while your doctors closely monitor how your tumor responds and how you tolerate the medication. You would need to have already completed surgery and radiation therapy before starting the study. Regular follow-up visits, imaging scans (MRI), and blood work would track whether the medication is helping slow or stop your tumor's growth, and the study team would watch for any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States